Belfast City Hospital

Belfast, Northern Ireland BT9 7AB

1 studies enrolling now · 12 studies all time

What they study most

Advanced Non-small Cell Lung Cancer, HER2 Mutation, Borderline Ovarian Serous Tumor, Breast Adenocarcinoma, Clear Cell Renal Carcinoma, Community-acquired Pneumonia, Influenza, COVID-19, Cystic Fibrosis, Fallopian Tube Cancer, Heart Failure, High Risk Essential Thrombocythemia, High Risk Polycythemia Vera, Hormone Receptor Positive, Metastatic Colorectal Cancer

Studies at this site

• A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2) — Recruiting now
• Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia — Recruiting now
• Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer — Completed
• Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial) — Running, not enrolling
• An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer. — Completed
• Strategic MAnagement to Optimize Response To Cardiac Resynchronization Therapy Registry — Completed
• Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous or Endometrioid Ovarian Cancer (ARIEL3) — Completed
• Trial to Evaluate Efficacy and Safety of Lenabasum in Cystic Fibrosis — Completed
• Evaluation of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough — Completed
• TroVax Renal Immunotherapy Survival Trial — Completed
• Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET) — Completed
• Study of Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older With the G551D Mutation — Completed